34133-58-9

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DIAMINO-PHENOL is used as an intermediate in the synthesis of various pharmaceutical compounds. It serves as a building block for the production of drugs that target specific diseases and conditions. One such application is in the preparation of febuxostat (F229000), a non-purine xanthine oxidase inhibitor used as a treatment for hyperuricaemia and chronic gout. Febuxostat helps to lower uric acid levels in the blood, providing relief from the symptoms associated with these conditions.
Used in Chemical Synthesis:
2,4-DIAMINO-PHENOL is also used as a chemical intermediate in the synthesis of various organic compounds, including dyes, pigments, and polymers. Its reactivity with other chemical groups allows for the formation of a wide range of products with diverse applications in the chemical industry.
Used in Analytical Chemistry:
Due to its ability to form complexes with metal ions, 2,4-DIAMINO-PHENOL is employed as a reagent in analytical chemistry for the detection and quantification of certain metal ions. This property makes it useful in various analytical techniques, such as spectrophotometry and chromatography, where the detection and measurement of metal ions are crucial.
Used in Research and Development:
2,4-DIAMINO-PHENOL is utilized in research and development for the study of its chemical properties, reactivity, and potential applications in various fields. Researchers use 2,4-DIAMINO-PHENOL to explore new synthetic routes, develop novel materials, and investigate its biological activities, which could lead to the discovery of new drugs or other useful products.

InChI:InChI=1/C8H4N2O/c9-4-6-1-2-8(11)7(3-6)5-10/h1-3,11H

Upstream product

• 615-58-7 2,4-dibromophenol 
• 544-92-3 copper(I) cyanide 
• 2976-30-9 1-methanesulfonyl-4-nitrobenzene 
• 151-50-8 potassium cyanide 
• 4387-30-8 4-chloro-1,3-benzenedicarbonitrile 
• 52054-41-8 4-nitroisophthalonitrile 
• 62-53-3 aniline 
• 94353-39-6 2,4-dicyanophenyl acetate 
• 1885-29-6 anthranilic acid nitrile 
• 67-56-1 methanol 
• 619-72-7 4-nitrobenzonitrile 
• 36914-79-1 acetic acid 2,4-dibromophenyl ester 
• 22433-92-7 2,4-dicyano-1-methoxybenzene 
• 90-02-8 salicylaldehyde 

Downstream Products

• 34633-30-2 5-bromo-4-hydroxyisophthalonitrile 
• 34633-31-3 4-hydroxy-5-iodoisophthalonitrile 
• 37142-39-5 4-(2-bromoethoxy)benzonitrile 
• 917226-68-7 4-(3-bromopropoxy)isophthalonitrile 
• 51282-86-1 2.4-Dicyanphenoxy-essigsaeure-ethylester 
• 54176-51-1 5-bromo-4-hydroxyisophthalic acid dimethyl ester 
• 1342299-81-3 6-(methoxycarbonyl)chroman-8-carboxylic acid 
• 95088-64-5 3-bromo-2-hydroxy-5-(methoxycarbonyl)benzoic acid 
• 1342299-76-6 C₁₆H₁₃BrO₅ 
• 1342299-77-7 C₁₉H₁₇BrO₅ 
• 1342299-78-8 C₁₈H₁₆O₅ 
• 1342299-79-9 C₂₁H₂₀O₅ 
• 1342299-80-2 C₁₉H₁₆O₅ 
• 1342299-85-7 C₁₈H₁₅BrO₆ 

Relevant academic research and scientific papers

The Synthesis and Transition Temperatures of Ester Derivatives of 2-Fluoro-4-hydroxy- and 3-Fluoro-4-hydroxybenzonitriles also Incorporating Aliphatic Ring Systems

The synthesis and liquid-crystal transition temperatures of forty ester derivatives of 2-fluoro-4-hydroxybenzonitrile and 3-fluoro-4-hydroxybenzonitrile are reported.The esters contain the trans-1,4-disubstituted cyclohexane or the 1,4-disubstituted bicyclooctane rings (some contain an additional phenyl ring).Many of the novel F-substituted esters exhibit substantially higher nematic-isotropic transition temperatures than the corresponding unsubstituted esters.The order of clearing points of these laterally substituted esters differing only in the presence of a benzene ring and the above-mentioned rings is established.

Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors

In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic acid derivatives that presented excellent in vitro xanthine oxidase (XO) inhibitory potency. To further investigate the structure-activity relationships of these compounds, the imidazole ring was transformed to a pyrimidine ring to design 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acids (8a-8j), 2-(4-alkoxy-3-cyano)phenyl-4-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acids (9c, 9e, 9j, 9l) and 2-(4-alkoxy-3-cyano)phenyl-6-imino-1,6-dihydropyrimidine-5-carboxylic acids (10c, 10e, 10j, 10l). These compounds exhibited remarkable in vitro XO inhibitory potency with IC50 values ranging from 0.0181 μM to 0.5677 μM. Specifically, compounds 10c and 10e, with IC50 values of 0.0240 μM and 0.0181 μM, respectively, emerged as the most potent XO inhibitors, and their potencies were comparable to that of febuxostat. Structure-activity relationship analysis revealed that the methyl group at 4-position of pyrimidine ring could damage the potency, and the XO inhibitory potency was maintained when carbonyl group was changed to an imino group. Lineweaver-Burk plot analysis revealed that the representative compound 10c acted as a mixed-type inhibitor. A potassium oxonate induced hyperuricemia model in rats was chosen to further confirm the hypouricemic effect of compound 10c, and the results showed that compound 10c (5 mg/kg) was able to significantly lower the serum uric acid level. Furthermore, in acute oral toxicity study, no sign of toxicity was observed when the mice were administered with a single 2000 mg/kg oral dose of compound 10c. These results suggested that compound 10c was a potent and promising uric acid-lowing agent for the treatment of hyperuricemia.

Preparation method and use of 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative

The invention belongs to the technical field of medicines, and relates to a preparation method and a use of a 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative. The invention provides the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative represented by general formula I, or a pharmaceutically acceptable salt, an isomer, a polymorph and a medicinal solvate thereof, and further provides an intermediate for preparing the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative or the pharmaceutically acceptable salt thereof. The structure of the intermediate is representedby general formula II, III or IV; and in the formulas, R, R and R are as defined in claims and the description.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

PROCESS FOR THE PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to novel and improved processes for the preparation of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its pharmaceutically acceptable salts thereof. the present invention also provides the novel process for the preparation of crystalline forms of 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid compound of formula-1 and its intermediates.

New oxabispidine compounds for the treatment of cardiac arrhythmias

There is provided compounds of formula I, wherein R1, R2, R3, R41 to R46, X, Y and Z have meanings given in the description, which compounds are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Nonspecific medium effects versus specific group positioning in the antibody and albumin catalysis of the base-promoted ring-opening reactions of benzisoxazoles

The mechanisms by which solvents, antibodies, and albumins influence the rates of base-catalyzed reactions of benzisoxazoles have been explored theoretically. New experimental data on substituent effects and rates of reactions in several solvents, in an antibody, and in an albumin are reported. Quantum mechanical calculations were carried out for the reactions in water and acetonitrile, and docking of the transition state into a homology model of antibody 34E4 and an X-ray structure of human serum albumin was accomplished. A microenvironment made up of catalytic polar groups (glutamate in antibody 34E4 and lysine in human serum albumin) surrounded by relatively nonpolar groups is present in both catalytic proteins.

Aromatic Nitro-group Displacement Reactions. Part 3. Minor Products of the o-Cyanophenol Synthesis

In dipolar aprotic solvents, the action of cyanide ions on a moderately activated aromatic or heteroaromatic nitro-compound yields, in addition to the o-cyanophenol, a range of products generated through nitro-group reduction.

Aromatic Nitro group Displacement Reactions. Part 2. The Synthesis of Diarylamines and some Heteroaromatic Analogues.

In dipolar aprotic solvents, activated aromatic nitro-groups can usually be displaced by anilines of enhanced N-acidity in the presence of the heavier alkali-metal carbonates.When catalysed by potassium t-butoxide, however, attack occurs preferentially at other reactive centers in the molecule, except where the nitro-group is highly activated.Some of the resulting diarylamines (the term is here expanded to include arylaminoxanthen-9-ones) are intermediates in the synthesis of heterocycles.